CT增强检查评估埃克替尼治疗非小细胞肺癌的疗效解析.doc

CT增强检查评估埃克替尼治疗非小细胞肺癌的疗效 陈红1，杨照环1，刘海霞3，肖颖1，任淑华2，王海波1，刘华群1，房芳1 唐山市工人医院，河北 唐山 063000,1肿瘤科2胸外科3影像诊断科 [摘要] 目的 探讨CT动态增强检查评估埃克替尼治疗非小细胞肺癌（NSCLC）疗效的可行性及临床应用价值。方法 回顾性分析经病理证实的晚期NSCLC患者经分子靶向药物埃克替尼治疗前后的CT动态增强检查资料及临床资料，将患者按照RECIST 标准分为缓解组和未缓解组，测量并比较两组治疗前1周内及治疗后1月病灶CT动态增强检查结果。结果 分析测量45例患者，其中缓解组26例，未缓解组19例；两组患者治疗前病灶密度及强化程度无统计学差异，p﹥0.05；缓解组患者治疗后病灶密度及强化程度均减低，差异有显著统计学意义， p=0.000；未缓解组治疗后CT密度及强化程度较治疗前略增高，但差异无统计学意义， p﹥0.05。缓解组治疗后病灶密度及强化程度均低于未缓解组，差异有统计学意义，p﹤0.05。结论 NSCLC经过埃克替尼治疗后定量分析病灶密度变化及强化程度可以为疗效评估提供参考。 [关键词] 强化CT;非小细胞肺癌;埃克替尼;疗效评价 The Value of Contrast-Enhanced CT in Evaluating Curative Effect of Conmana for Non-Small Cell Lung Cancer 【Abstract】Purpose　To evaluate the value of contrast-enhanced CT imaging in diagnosing therapeutic effect of non-small cell lung cancer. Materials and Methods　Forty-five patients with non-small cell lung cancer proved histologically underwent contrast-enhanced CT scanning before and after therapy. All data were automatically analyzed and changes of each parameter before and after therapy were compared. Results　According to the response to therapy based on RECIST and followed up for 3months, 26 out of 45 patients obtained effective treatment, and 19 patients obtained ineffective treatment. The mean density and enhancement extent of lesions for 45 patients obtained effective treatment before treatment were no statistically difference than those obtained ineffective treatment (p﹥0.05).After treatment, the mean density and enhancement extent of lesions for 26 patients obtained effective treatment were significantly decreased than those before treatment (p=0.000). No obvious difference in any parameter for 16 patients obtained ineffective treatment was observed before and after treatment (P＞ 0.05). The mean density and enhancement extent of lesions for patients obtained effective treatment were significantly decreased than those patients obtained ineffective treatment(p﹤0.05).Conclusion　 Contrast-enhanced CT scanning can quantitatively assess the changes of